




# Podravka Group

*Always with a heart!*

Belgrade Stock Exchange Investor Conference, Belgrade, 15<sup>th</sup> November 2018





# **The Company**

**Business**

**Investment highlights**

**2017 results**


**1-9 2018 results**

# Podravka Group at a glance



## **BUSINESS:**

- Branded food – primary business,
- Generic pharmaceuticals.



## **2017 FIGURES:**

- HRK 4,111m (EUR 541m) of sales,
- HRK 5,106m (EUR 672m) of assets,
- 6,306 employees.


## **YEAR OF ESTABLISHMENT: 1947**

- 71 years in food production,
- 46 years in pharma production,
- Culinary institution in SEE.



## **HEADQUARTERS:**

- Koprivnica, Croatia.



## **MAIN MARKETS:**

- South East Europe,
- Central Europe,
- Eastern Europe.



## **SHARE LISTING:**

- Zagreb Stock Exchange, Croatia,
- 7,120,003 ordinary shares,
- MCap of HRK 2,506m (EUR 330m).\*

**Note:** all figures in this presentation are translated to euros at HRK/EUR FX rate of 7.6 to avoid FX differences; \*MCap on 31<sup>st</sup> October 2018, calculated on weighted average number of shares excluding treasury shares.

# Long tradition of food and pharmaceutical production



1934

Fruit processing and marmalade workshop by brothers Wolf established



1947

Wolf brothers workshop became publicly owned under Podravka name



1952

Condiments, dried and sterilized vegetables, etc. production established



1957

Famous Podravka soups production established



1958

Production of meat products established



1959

Vegeta, universal seasoning, production established



1970

Baby food production established



1972

Belupo pharmaceutical company established, pharmaceutical production established



1993

Podravka became a joint-stock company, free share trading from 1994



2012

Commencement of full-scale restructuring process



2015

Žito, Slovenian food producer, acquisition





2017

Construction of new pharmaceutical factory, the largest greenfield investment in Group history

# Podravka Group is present in 24 countries with subsidiaries and representative offices

## International network of subsidiaries and representative offices




## Own distribution network in 11 countries

1. Bosnia and Herzegovina
2. Czech Republic
3. Montenegro
4. Croatia
5. Hungary
6. Macedonia
7. Poland
8. Slovakia
9. Slovenia
10. Serbia
11. Russia



## Podravka Group sales split by regions in 2017



Market	HRKm	EURm	%
Croatia	1,355	178	33.0%
Slovenia	742	98	18.0%
B&H	430	57	10.5%
Russia	264	35	6.4%
Other m.	1,320	173	32.1%
<b>Group</b>	<b>4,111</b>	<b>541</b>	<b>100.0%</b>

# Institutional investors provide stable ownership structure

## Management board



**Marin Pucar,**  
MB president



**Ljiljana Šapina,**  
MB member



**Davor Doko,**  
MB member



**Hrvoje Kolarić,**  
MB member



**Marko Đerek,**  
MB member

## Supervisory board

### President:

- Dubravko Štimac → president of MB of PBZ CO OPF


### Vice President:

- Luka Burilović → president of Croatian Chamber of Economy

### Members:

- Ksenija Horvat → workers representative
- Krunoslav Vitelj → director of regional Croatian Chamber of Economy
- Dajana Milodanović → banker in HPB
- Damir Grbavac → president of MB of RBA OPF
- Petar Vlaić → president of MB of Erste Plavi OPF
- Ivana Matovina → professional auditor
- Petar Miladin → academy professor of law

## Shareholder structure as at 30 September 2018



## Audit committee

### President:

- Ivana Matovina

### Members:

- Dubravko Štimac, Petar Vlaić

## Remuneration committee

### President:

- Luka Burilović

### Members:

- Dubravko Štimac, Petar Miladin

## Corporate governance committee


### Members:

- Petar Miladin, Petar Vlaić, Luka Burilović

# Snapshot of key financial figures

## Reported sales revenues split

### Reported sales revenues in 2017




2017 sales	HRKm
Food	3,244
Pharma	867
Group	4,111

2017 sales	EURm
Food	427
Pharma	114
Group	541

## Normalized EBITDA split

### Normalized EBITDA in 2017




2017 EBITDA	HRKm
Food	277
Pharma	157
Group	435



2017 EBITDA	EURm
Food	36
Pharma	21
Group	57

## Stable cash position

### Net cash flow from operating activities as % of sales revenues<sup>1</sup>




## Low and sustainable debt level<sup>2</sup>



<sup>1</sup>Due to sales revenues reclassification in 2016, 2012-2014 % are made by approximation.

<sup>2</sup>2017 figures.



The Company


**Business**

Investment highlights


2017 results

1-9 2018 results

# A well diversified product portfolio divided in two business areas



# Culinary category is a cornerstone of food business

	Food segment products overview		2017 sales; % of total		
<b>BU ŽITO AND LAGRIS</b> <ul style="list-style-type: none"> <li>Core food, bakery and mill products, tea, confectionery, cereals for adults, private labels, service production.</li> </ul>	      	HRK 894m	EUR 118m	21.7%	
<b>BU CULINARY</b> <ul style="list-style-type: none"> <li>Seasonings, monospices, soups, ready-to-cook meals and bouillons, food mixes, private labels, service production.</li> </ul>	      	HRK 880m	EUR 116m	21.4%	
<b>BU PODRAVKA FOOD</b> <ul style="list-style-type: none"> <li>Condiments, tomato, sauces, fruit, vegetables, Podravka flour, private labels, service production.</li> </ul>	      	HRK 389m	EUR 51m	9.5%	
<b>BU BABY FOOD, SWEETS &amp; SNACKS</b> <ul style="list-style-type: none"> <li>Dehydrate baby food, cream spreads, cereals, sweets, snacks, drinks, private labels, service production.</li> </ul>	      	HRK 378m	EUR 50m	9.2%	
<b>BU MEAT PRODUCTS, MEALS AND SPREADS</b> <ul style="list-style-type: none"> <li>Canned meat, sausages, other meat, Food Solution, private labels, service production.</li> </ul>	   	HRK 271m	EUR 36m	6.6%	
<b>BU FISH</b> <ul style="list-style-type: none"> <li>Fish products, private labels, service production.</li> </ul>	    	HRK 175m	EUR 23m	4.2%	
<b>OTHER SALES</b> <ul style="list-style-type: none"> <li>Trade goods, other.</li> </ul>	   	HRK 257m	EUR 34m	6.2%	

# Prescription drugs category is a cornerstone of pharmaceutical business

## Pharmaceutical segment products overview

2017 sales; % of total

### PRESCRIPTION DRUGS

- For skin disorders
- For heart and blood vessels,
- For central nervous system,
- For 8 more areas.



HRK 631m    EUR 83m    15.3%

### NON-PRESCRIPTION PROGRAMME

- OTC medicine,
- Dietary products,
- Natural products.



HRK 98m    EUR 13m    2.4%

### OTHER SALES

- Trade goods,
- Services.



HRK 139m    EUR 18m    3.4%

# High-quality brands with exceptional recognisability and strong international potential



## VEGETA

- Culinary brand whose products are sold in over 60 countries in the world,
- Synonym for universal seasoning category in the Adria region,
- For years No. 1 FMCG brand in Croatia and among top 3 in Adria region,

- Number 1 brand in Europe in universal food seasoning category,
- Superbrand award in more than 15 European countries.

Vol. MP <sup>1</sup>	ADRIA	POL	SLK	CZE	RUS
Vegeta	1	3	1	3	3



## PODRAVKA SOUPS

- Dehydrated instant soups,
- Sold in 25 countries around the world,
- Market leader or among top 3 in the Adria region,

- Quadal (Quality Medal) award in Croatia,
- Best Buy award in Croatia and B&H.

Vol. MP <sup>1</sup>	CRO	SLO	B&H	SER	MAC	RUS
Soups	1	4	1	2	1	6



## LINO

- Umbrella brand for dehydrated baby food, cream spreads and cereals,
- Synonym for baby food category in Adria region,
- Sold in more than 20 countries around the world,

- Trusted brand award and Best Buy award winner in Croatia,
- Superbrand awards winner in Croatia, Slovenia and B&H.

Vol. MP <sup>1</sup>	CRO	SLO	B&H	SER
Lino	1	1	1	1



## DOLCELA

- Product for preparation of sweets and ready-made sweets,
- Market leader/strong No. 2 brand in Adria region,
- Sold in 20 countries around the world,

- Quadal (Quality Medal) award in Croatia,
- Best Buy award in Croatia and B&H.

Vol. MP <sup>1</sup>	CRO	SLO	B&H
Dolcela	1	2	1



## EVA (MEDITERRANEAN ASSORTMENT)

- One of the most recognisable brands in canned fish category in the Adria region,
- Widest range of canned fish – tuna, sardines, mackerel and Baltic fish.

- Quadal (Quality Medal) award and Superior taste award in Croatia,
- Best Buy award in Croatia and B&H.

Vol. MP <sup>1</sup>	CRO	SLO	B&H	SER
Eva	1	6	1	3




## BELUPO DERMATICS

- Strong international position in niche dermatology segment.

Vol. MP <sup>2</sup>	CRO	RUS	CZE	SLO	B&H	SER	MAC	SLK
D07 <sup>3</sup>	1	5	1	2	1	2	1	1

<sup>1</sup>Source: Nielsen; <sup>2</sup>Source: IMS; <sup>3</sup>Corticosteroids for the treatment of skin disorder.



The Company



Business

**Investment highlights**

2017 results

1-9 2018 results

# Continuous restructuring process in order to improve efficiency and profitability




# Financial position under the influence of one-off items

## Restructuring related one-off items burdened profitability

(in HRK <sub>m</sub> )	2012	2013	2014	2015	2016	2017	1-9 2018
Value adjustments	(32)	(81)	(28)	(35)	(11)	(89)	-
Severance payments	(50)	(57)	(72)	(41)	(12)	(40)	(3)
Other	(44)	5	10	298 <sup>1</sup>	8	(18)	14
<b>Total net one-offs</b>	<b>(126)</b>	<b>(133)</b>	<b>(90)</b>	<b>222</b>	<b>(15)</b>	<b>(147)</b>	<b>11</b>


<sup>1</sup>HRK 116m of gain on a bargain purchase from Žito acquisition (badwill), HRK 164m of deferred tax income from Croatian government's incentives for the construction of new Belupo pharmaceutical factories, HRK 19m refers to other items.

## Normalized profitability margins movement<sup>2</sup>




**Note:** Due to sales revenues reclassification in 2016, 2013-2014 margins are made by approximation.

## Normalized return rates movement<sup>2</sup>



## Normalized debt level movement<sup>2</sup>



<sup>2</sup>2015 figures include pro-forma Podravka Group and Žito Group full year figures, excluding consolidation effects and tax incentives for Belupo factories.

# Expansion of pharmaceutical capacities to satisfy international demand

## Construction of new pharmaceutical facility

### Project:

- Production facility for solid oral forms,
- Production facility for semi solid and liquid forms,
- Project started in 2015, ended in 2017.

### Project reasoning:


- Insufficient production capacities due to perennial volume growth → 150% capacity increase,
- Investment in new technologies that will enable production of new-age products in the form of foams, sprays, bandages etc.

### Project financing:

- Total value of investment HRK 535m (EUR 70m),
- 55% loan from HBOR, 45% own funds,
- Government incentive through income tax benefits in the amount of 40% of total investment.

### Business reasons for choosing Croatia as facilities location:



- High speed in obtaining all permits,
- Tax incentives for strategic investments,
- Availability of highly-educated workforce at acceptable cost level,
- Incentives for hiring young workforce,
- Proximity to other Belupo locations.



# Podravka's share price movement in 1-9 2018

(HRK; units)	2017	1-9 2018	% change
Weighted average daily price	362.4	297.9	(17.8%)
Average daily number of transactions	18	11	(34.8%)
Average daily volume	1.249	1.378	10.4%
Average daily turnover	452,528	410,631	(9.3%)
Reported earnings per share	2.6	21.6	721.6%
Normalized earnings per share	23.8	34.2	43.6%

Analysts	Recommendation	Target price	Potential <sup>1</sup>
 InterCapital	Under review	-	n/a
 Raiffeisen BANK	Hold	HRK 371	6.3%
 ERSTE Group	Accumulate	HRK 405	16.0%
 UniCredit	Buy	HRK 399	14.3%
 WOOD & COMPANY	Hold	HRK 354	1.4%




Peer group multiples <sup>2</sup>	EV/Sales	EV/EBITDA	EV/EBIT	P/B	P/E
Weighted average peer group	1.9	12.0	17.1	2.6	18.8
Normalized weight. av. peer group <sup>3</sup>	1.6	10.2	16.0	2.0	16.5
Podravka Group reported	0.8	6.7	15.2	0.8	16.2
Podravka Group normalized <sup>4</sup>	0.8	6.6	10.3	0.8	10.2

**Peer group food:** Atlantic Grupa, Ebro, Hochdorf, La Doria, McCormick, Orkla;

**Peer group pharma:** Alkaloid, Richter Gedeon, Hikma Pharmaceuticals, Krka, Recordati, Stada Arzneimittel.

<sup>1</sup>Compared to the last price on 30<sup>th</sup> September 2018; <sup>2</sup>Obtained from Bloomberg on 31<sup>st</sup> October 2018; <sup>3</sup>Calculated excluding max. and min. values; <sup>4</sup>Normalized for items stated in the publication of 1-9 2018 and 2017 results.



The Company



Business

Investment highlights

**2017 results**

1-9 2018 results

# Strong growth of Pharmaceutical segment sales in 2017



## Adjusted sales revenues exclude/include:

- **Beverages business** → sold at the end of 2016; HRK 82.2m excluded from 2016 and HRK 0.4m from 2017 to provide like-for-like comparison,
- **One-off sales of BU Meat** → in February 2016 extraordinary delivery of buffer stock to the Ministry of Economy was made related to the migration of population from war-torn areas; HRK 12.0m excluded from 2016 to provide like-for-like comparison,
- **Inconsistencies in the treatment of recording revenue** → identified in the Food segment on the Russian market, largely a result of a different trade marketing activities classification; HRK 25.4m excluded from 2016 and HRK 2.2m included in 2017 to provide LFL comparison.



## Estimated net foreign exchange (FX) impact on reported sales revenues:

HRKm	Own brands	Other sales	Total	Currency	HRKm
Food	(6)	(0)	(6)	EUR	(15)
Pharmaceuticals	14	(1)	13	RUB	23
Group	8	(1)	7	Other	(1)
				Total	7

- FX impact on sales revenues shows for how much sales revenues would have been higher or lower in 2017 if FX rates had remained on the same levels as in 2016.

<sup>1</sup>Performance in 2017 compared to 2016 excluding the estimated net impact of foreign exchange differences.

# Business units facing internal and external challenges





## Adjusted business unit and category performance in 2017<sup>1</sup>:

- **BU Žito and Lagris (-0.0% excl. FX)** → sales increase in Italy, Germany and Spain due to the product range extension and distribution, annulled by unlisting of a certain bakery range that began at the end of 2016 on the Slovenian market,
- **BU Culinary (-2.0% excl. FX)** → lower sales primarily due to lower sales in Western Europe related to the sales dynamics to the new distributor,
- **BU Podravka food (+1.8% excl. FX)** → higher sales on the back of extended range of vegetables in the Croatian market,
- **BU Baby food, sweets and snacks (-1.4% excl. FX)** → lower sales of the snacks range due to poor acceptance of the redesign launched in mid 2016,
- **BU Meat products, meat solutions and savoury spreads (+2.1% excl. FX)** → sales growth of Food Solution sub segment,
- **BU Fish (+0.8% excl. FX)** → sales growth primarily due to higher sales of own brands in the Croatian market,
- **Prescription drugs (+5.5% excl. FX)** → revenue growth in the Russian market as a consequence of the product range extension and positive FX effect,
- **Non-prescription programme (+1.3% excl. FX)** → extension of the product range and positive effect of foreign exchange differences in the Russian market; implemented selling and marketing activities in the Croatian market,
- **Other sales (+4.3% excl. FX)** → trade goods sales growth.

<sup>1</sup>Percentages in the text relate to performance in 2017 compared to 2016.

# Positive developments of Eastern Europe region in 2017



## Adjusted region performance in 2017<sup>1</sup>:

- **Adria (+0.1% excl. FX)** → food sales 0.6% lower due to the decrease of the BU Žito and Lagris revenues on the Slovenian market as a result of unlisting of a certain bakery range that began at the end of 2016. The most significant sales growth was recorded by the BU Podravka food due to expansion of the vegetables range distribution on the Croatian market; **pharmaceuticals** sales were slightly lower than in 2016,
- **Central Europe (-0.3% excl. FX)** → food sales 0.7% lower due to lower sales of trade goods of the Lagris company that was offset by higher sales of own brands; **pharmaceuticals** sales 9.8% higher due to growth in markets of Poland and Czech Republic,

- **Western Europe and Overseas (+1.1% excl. FX)** → food sales 0.6% higher due to the extension of the product range and distribution of the BP Žito in the markets of Italy, Germany and Spain and from trade goods sales growth. This positive effect was partially offset by a decrease in sales due to sales dynamics with the new distributor to which total sales in the last two months of 2016 amounted to the sales realised in the first four and half months of 2017; **pharmaceuticals** sales records a mild revenue growth in the market of Germany,
- **Eastern Europe (+12.3% excl. FX)** → food sales 7.8% higher due to selling activities in the Culinary range with the most significant customers and the increase in sales of trade goods of the Lagris company; **pharmaceuticals** sales rose 33.1% due to extension of product range,
- **New markets (+22.5% excl. FX)** → food sales 11.1% higher due to sales growth in BU Baby food, sweets and snacks and of trade goods of the company Lagris; **pharmaceuticals** sales 41.7% higher due to the Prescription drugs category growth in the market of Turkey.

<sup>1</sup>Percentages in the text relate to performance in 2017 compared to 2016.

# Food profitability burdened by significant one-off items in 2017

Food segment (in HRK <sub>m</sub> )	REPORTED				NORMALIZED <sup>1</sup>			
	2016	2017	Δ	%	2016	2017	Δ	%
Sales revenue	3,370	3,244	(127)	(3.8%)	3,370	3,244	(127)	(3.8%)
Gross profit	1,107	1,039	(68)	(6.1%)	1,107	1,058	(49)	(4.4%)
EBITDA	317	243	(74)	(23.3%)	314	277	(37)	(11.7%)
EBIT	158	8	(150)	(94.7%)	165	134	(30)	(18.3%)
Net profit after MI	111	(30)	(141)	(126.6%)	121	83	(38)	(31.6%)
Gross margin	32.8%	32.0%		-80 bp	32.8%	32.6%		-23 bp
EBITDA margin	9.4%	7.5%		-191 bp	9.3%	8.6%		-77 bp
EBIT margin	4.7%	0.3%		-444 bp	4.9%	4.1%		-74 bp
Net profit margin after MI	3.3%	(0.9%)		-421 bp	3.6%	2.6%		-104 bp

## Food segment profitability in 2017:

- **Normalized gross profit** → impacted by lower sales revenues, but also by unfavourable changes in sales structure,
- **Normalized EBIT** → additionally impacted by lower profitability of the Žito Group, higher expenses of exercised share options (HRK 12.5m in 2017; HRK 7.0m in 2016), unfavourable movements of FX differences from trade receivables and payables (HRK 5.2m losses in 2017; HRK 3.1m gains in 2016),
- **Normalized net profit after MI** → additionally impacted by unfavourable movements of FX differences on borrowings (HRK 10.6m losses in 2017; HRK 8.6m gains in 2016) which was partly mitigated by lower interest expense.

## One-off impacts in HRK<sub>m</sub>

	2016	2017
Value adjustments	(9)	(89)
Severance payments	(12)	(31)
Other (expenses)/revenues above EBIT	14	(6)
ESOP <sup>2</sup> financial expenses	(2)	(3)
Deferred tax assets	(1)	16

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process; <sup>2</sup>Employee stock ownership programme.

# Pharma profitability positively impacted by favourable sales structure

Pharmaceuticals segment (in HRKm)	REPORTED				NORMALIZED <sup>1</sup>			
	2016	2017	Δ	%	2016	2017	Δ	%
Sales revenue	815	867	52	6.4%	815	867	52	6.4%
Gross profit	428	445	17	3.9%	431	470	40	9.2%
EBITDA	154	131	(23)	(15.2%)	157	157	0	0.0%
EBIT	111	83	(28)	(25.2%)	116	117	1	0.9%
Net profit after MI	71	48	(23)	(32.7%)	76	83	6	8.1%
Gross margin	52.5%	51.3%		-125 bp	52.8%	54.2%		+139 bp
EBITDA margin	18.9%	15.1%		-383 bp	19.3%	18.1%		-115 bp
EBIT margin	13.6%	9.5%		-404 bp	14.2%	13.5%		-74 bp
Net profit margin after MI	8.7%	5.5%		-321 bp	9.4%	9.5%		+15 bp

## Pharmaceuticals segment profitability in 2017:

- **Normalized gross profit** → impacted by increase in revenues, but also by favourable changes in sales structure,
- **Normalized EBIT** → additionally impacted by higher marketing expenses due to higher investments in the Russian market and extremely unfavourable movements of FX differences from trade receivables and payables (HRK 7.3m losses in 2017; HRK 15.4m gains in 2016). Share option expenses were slightly below the comparative period (HRK 0.2m in 2017; HRK 1.0m in 2016),
- **Normalized net profit after MI** → additionally impacted by higher financial income and positive movement of FX differences on borrowings (HRK 0.3m gains in 2017; HRK 2.6m losses in 2016).

## One-off impacts in HRKm

	2016	2017
New pharmaceuticals factory expenses	(2)	(25)
Severance payments	(1)	(9)
Value adjustments	(2)	-
ESOP <sup>2</sup> financial expenses	(1)	(1)
Deferred tax assets	0	-

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process; <sup>2</sup>Employee stock ownership programme.

# Group profitability movement under the influence of Food segment profitability

Podravka Group (in HRK <sub>m</sub> )	REPORTED				NORMALIZED <sup>1</sup>			
	2016	2017	Δ	%	2016	2017	Δ	%
Sales revenue	4,186	4,111	(74)	(1.8%)	4,186	4,111	(75)	(1.8%)
Gross profit	1,535	1,484	(51)	(3.3%)	1,538	1,528	(10)	(0.6%)
EBITDA	471	374	(97)	(20.6%)	472	435	(37)	(7.8%)
EBIT	269	91	(178)	(66.1%)	280	251	(29)	(10.4%)
Net profit after MI	182	18	(164)	(90.0%)	198	166	(32)	(16.2%)
Gross margin	36.7%	36.1%		-58 bp	36.7%	37.2%		+43 bp
EBITDA margin	11.3%	9.1%		-216 bp	11.3%	10.6%		-69 bp
EBIT margin	6.4%	2.2%		-421 bp	6.7%	6.1%		-59 bp
Net profit margin after MI	4.4%	0.4%		-391 bp	4.7%	4.0%		-70 bp

## Group profitability in 2017:

- **Normalized gross profit** → Pharmaceuticals segment gross profit growth to the high extent compensated for the lower gross profit of the food segment,
- **Normalized EBIT** → additionally impacted by lower profitability of the Žito Group, higher expenses of exercised share options (HRK 12.8m in 2017; HRK 8.0m in 2016), unfavourable movements of FX differences from trade receivables and payables (HRK 12.5m losses in 2017; HRK 18.5m gains in 2016),
- **Normalized net profit after MI** → additionally impacted by unfavourable movements of FX differences on borrowings (HRK 10.3m losses in 2017; HRK 6.0m gains in 2016) which was partly mitigated by lower interest expense.


## One-off impacts in HRK<sub>m</sub>

	2016	2017
Value adjustments	(11)	(89)
Severance payments	(12)	(40)
New pharmaceuticals factory expenses	(2)	(25)
Other (expenses)/revenues above EBIT	14	(6)
ESOP <sup>2</sup> financial expenses	(3)	(4)
Deferred tax assets	(1)	16

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process; <sup>2</sup>Employee stock ownership programme.

# Successful cost side optimization in 2017

Operating expenses 17 vs. 16 % change	REPORTED	NORMALIZED <sup>1</sup>
Cost of goods sold (COGS)	(0.9%)	(2.4%)
General and administrative expenses (G&A)	10.8%	0.7%
Sales and distribution costs (S&D)	6.6%	(1.5%)
Marketing expenses (MEX)	(0.5%)	(0.5%)
Other expenses / revenues, net	n/a	n/a
<b>Total</b>	<b>2.6%</b>	<b>(1.2%)</b>




<sup>1</sup>Normalized for one-off impacts.

## Key highlights of normalized operating expenses in 2017:

- Cost of goods sold (COGS):**
  - Lower 2.4% primarily as a result of lower sales in the Food segment,
- General and administrative expenses (G&A):**
  - Higher 0.7% than in the comparative period primarily due to the higher costs of exercised share options (HRK 12.8m in 2017; HRK 8.0m in 2016),
- Sales and distribution expenses (S&D):**
  - Lower 1.5% due to, among other, disinvestment of the Beverages business that was incurring significant distribution costs,
- Marketing expenses (MEX):**
  - Lower 0.5% as a result of fewer marketing activities in the Food segment, while the Pharmaceuticals segment recorded an increase in marketing expenses, primarily in the Russian market,
- Other expenses / revenues, net:**
  - Item includes FX differences from trade receivables and trade payables that were HRK 12.5m negative in 2017, while in 2016 they were HRK 18.5m positive. In 2017, other expenses/revenues item amounted to negative HRK 2.5m, while in the comparative period it amounted to positive HRK 25.4m.


# Lower interest expenses and weighted average cost of debt reflects successful debt management

<i>(in HRKm)</i> <sup>1</sup>	2016	2017	% change
Net debt	1,042	909	(12.7%)
Interest expense	31	27	(14.6%)
Net debt / normalized EBITDA	2.2	2.1	(5.3%)
Normalized EBIT / interest expense	8.9	9.3	4.9%
Equity to total assets ratio	55.4%	57.2%	+187 bp



## Key highlights:

- Net debt decrease → repayment of a part of borrowings,
- Lower interest expenses → repayment of a part of borrowings,
- Net debt/normalized EBITDA drop due to lower net debt,
- **Weighted average cost of debt:**
  - As at 31 December 2017 → 2.0%,
  - As at 31 December 2013 → 4.3%.




<sup>1</sup>All P&L figures are calculated on the trailing 12 months level, while BS figures are taken at the end of period.

## Stable level of net cash from operating activities

Working capital movement in BS	31 December 2017 / 31 December 2016		Impact
Inventories		4.2%	<ul style="list-style-type: none"> <li>Increased plans for the production of own products and trade goods led to higher level of inventories.</li> </ul>
Trade and other receivables		(19.5%)	<ul style="list-style-type: none"> <li>Value adjustment of Agrokor receivables, a portion of recourse bills of exchange was collected, lower sales in Food segment, better collection in the Pharmaceuticals segment in the domestic and foreign markets.</li> </ul>
Trade and other payables		(10.6%)	<ul style="list-style-type: none"> <li>Settlement of a portion of trade payables for the construction of the new pharmaceuticals factory and the repurchase of recourse bills of exchange from a factoring company. Recourse bills of exchange on 31 December 2016 were booked under other payables position.</li> </ul>


(in HRKm)	2016	2017	Δ
Net cash from operating activities	477	473	(3)
Net cash from investing activities	(359)	(191)	168
Net cash from financing activities	(72)	(258)	(186)
<b>Net change of cash and cash equivalents</b>	<b>46</b>	<b>25</b>	<b>(21)</b>

- **CAPEX** in 2018 is expected to be at the level of HRK 217m, in 2019 at the level of HRK 250 - 300m, and in 2020 and 2022 at the level of HRK 200m.



## One-off items in 2017 and 2016

One-off items <i>(in HRK<sub>m</sub>)</i>	2016			2017			Δ		
	Group	Food	Pharma	Group	Food	Pharma	Group	Food	Pharma
+expense related to China closing	-	-	-	(1)	(1)	-	(1)	(1)	-
+severance payments expenses	(13)	(12)	(1)	(40)	(31)	(9)	(27)	(19)	(8)
+revenues from Beverages sales	8	8	-	-	-	-	(8)	(8)	-
+revenues from reverse leasing Umag	7	7	-	-	-	-	(7)	(7)	-
+value adjustments (expenses)/revenues	(11)	(9)	(2)	(89)	(89)	-	(78)	(80)	2
+ <i>Warzyvko &amp; Perfecta brands</i>	-	-	-	(18)	(18)	-	(18)	(18)	-
+ <i>inventories in Serbia</i>	-	-	-	(11)	(11)	-	(14)	(14)	-
+ <i>assets in MENA</i>	-	-	-	(1)	(1)	-	(1)	(1)	-
+ <i>assets in Africa</i>	-	-	-	(16)	(16)	-	(16)	(16)	-
+ <i>Beverages assets</i>	(9)	(9)	-	-	-	-	9	9	-
+ <i>Agrokor receivables</i>	-	-	-	(44)	(44)	-	(44)	(44)	-
+ <i>other one-off value adjustments</i>	(2)	0	(2)	1	1	-	3	1	2
+amortization expenses	-	-	-	(3)	(3)	-	(3)	(3)	-
+ESOP programme expenses	(3)	(2)	(1)	(4)	(3)	(1)	(1)	(1)	(0)
+new Belupo factory expenses (+amortization)	(2)	-	(2)	(25)	-	(25)	(23)	-	(23)
+other one-off expenses	-	-	-	(2)	(2)	-	(2)	(2)	-
+deferred tax assets	(1)	(1)	0	16	16	-	17	17	(0)



The Company


Business

Investment highlights

2017 results

**1-9 2018 results**

# Strong top-line growth in both business segments



## Net foreign exchange (FX) impact on sales revenues:

HRKm	Own brands	Other sales	Total	Currency	HRKm
Food	(15)	1	(14)	RUB	(25)
Pharmaceuticals	(18)	(0)	(18)	EUR	(4)
Group	(33)	1	(32)	Other	(3)
				Total	(32)

- FX impact on sales revenues shows for how much sales revenues would have been higher or lower in 1-9 2018 if FX rates had remained on the same levels as in 1-9 2017.

### Food segment in 1-9 2018<sup>1</sup>:

- Own brands** → 3.8% higher sales (+4.5% excl. FX), primarily due to the continued growth in sales of business units Culinary, Baby food, sweets and snacks, Žito and Lagris, as a result of increased selling and marketing activities, product innovation and expanded distribution of certain categories,
- Other sales** → 8.3% lower sales (-8.9% excl. FX), as a consequence of decrease in sales of trade goods,
- Total Food** → 2.8% higher sales (+3.4% excl. FX).

### Pharmaceuticals segment in 1-9 2018<sup>1</sup>:


- Own brands** → 4.9% higher sales (+8.4% excl. FX), primarily due to the increase in sales in the Russian market and higher sales in the markets of the Adria and Central Europe regions,
- Other sales** → 3.4% higher sales (+3.6% excl. FX) as a result of higher sales of trade goods in Farmavita and in Deltis Pharm pharmacies,
- Total Pharmaceuticals** → 4.7% higher sales (+7.6% excl. FX).

### Podravka Group in 1-9 2018<sup>1</sup>:

- Own brands** → 4.0% higher sales (+5.2% excl. FX),
- Other sales** → 4.2% lower sales (-4.5% excl. FX),
- Total Podravka Group** → 3.2% higher sales (+4.3% excl. FX).

<sup>1</sup>Percentages in the text relate to performance in 1-9 2018 compared to 1-9 2017.

# Significant organic growth of 4.0% with BU Žito and Lagris as main driver




## Business unit and category performance in 1-9 2018<sup>1</sup>:

- BU Žito and Lagris (+6.1%; +6.3% excl. FX)** → continuous growth in the Bakery and mill products in the market of Slovenia and markets of Western Europe, as a result of stronger selling activities and expanded distribution,
- BU Culinary (+2.9%; +4.4% excl. FX)** → sales growth in most regions primarily driven by Seasonings and Soups categories, as a consequence of intensive promotional activities,
- BU Baby food, sweets and snacks (+8.7%; +8.9% excl. FX)** → sales growth due to stronger marketing activities in categories Creamy spreads, Baby food and Snacks in the market of Croatia; new and innovated products of the Lino Lada brand continue to drive growth in the Creamy spreads category,
- BU Podravka food (+0.6%; +1.6% excl. FX)** → higher sales due to selling and marketing activities and expanded distribution in the Condiments, Tomato and Flour categories,
- BU Meat products, meat solutions and savoury spreads (-1.5%; -1.0% excl. FX)** → lower sales resulting from different dynamics of selling and marketing activities in market of Croatia and change of distributor in the DACH region,
- BU Fish (+1.7%; +1.6% excl. FX)** → higher sales primarily due to stronger selling and marketing activities in the Adria region market,
- Prescription drugs (+5.4%; +9.1% excl. FX)** → the most significant sales growth in the market of Russia due to higher demand, and in the markets of Adria and Central Europe regions,
- Non-prescription programme (+1.9%; +4.2% excl. FX)** → higher sales as a consequence of the growth in the OTC drugs subcategory in the market of Bosnia and Herzegovina due to increased focus on the non-prescription programme,
- Other sales (-4.2%; -4.5% excl. FX)** → lower trade goods sales revenues in the Food segment on the Croatian market.

<sup>1</sup>Percentages in the text relate to performance in 1-9 2018 compared to 1-9 2017.

# Positive sales trend continues in nearly all regions



## Region performance in 1-9 2018<sup>1</sup>:

- **Adria (+2.3%; +2.5% excl. FX)** → food sales 2.6% higher driven by sales growth in all business units, as a consequence of new and innovated products as well as selling and marketing activities; **pharmaceuticals** sales 1.2% higher due to organic growth and increase in other sales,
- **Central Europe (+7.2%, +6.7% excl. FX)** → food sales 6.5% higher with the most significant impact on the Food segment came from the Culinary business unit and from the Žito and Lagris business unit following stronger selling and marketing activities; **pharmaceuticals** sales rose 12.8% due to the increased demand and launching new products in the markets of Poland, the Czech Republic and Slovakia,

- **Western Europe and Overseas (+2.7%; +4.6% excl. FX)** → food sales 3.1% higher as a result of continuous expansion of the product range and distribution of the Žito and Lagris business unit in the markets of Italy, Germany and Spain; **pharmaceuticals** revenues recorded a mild decrease of HRK 1.1m due to changed dynamics of annual deliveries,
- **Eastern Europe (+9.0%, +22.2% excl. FX)** → food sales 2.8% lower which is primarily a consequence of the decrease in sales of the Podravka Food business unit that was not fully compensated by growth of Culinary business unit; **pharmaceuticals** sales rose 18.0% following the increased demand for the Prescription drugs category,
- **New markets (-15.2%; -14.8% excl. FX)** → food sales is HRK 3.3m lower because of the lower sales of the Lagris company trade goods in the Asian market; **pharmaceuticals** sales is HRK 0.4m lower.

<sup>1</sup>Percentages in the text relate to performance in 1-9 2018 compared to 1-9 2017.

## Strong growth of food profitability in 1-9 2018

Food segment (in HRK <sub>m</sub> )	REPORTED				NORMALIZED <sup>1</sup>			
	1-9 2017	1-9 2018	Δ	%	1-9 2017	1-9 2018	Δ	%
Sales revenue	2,372	2,439	67	2.8%	2,372	2,439	67	2.8%
Gross profit	757	827	70	9.3%	758	828	71	9.3%
EBITDA	170	281	111	65.1%	195	272	77	39.3%
EBIT	60	182	122	202.5%	85	173	88	103.0%
Net profit after MI	20	144	124	594.6%	48	133	85	177.5%
Gross margin	31.9%	33.9%		+201 bp	31.9%	34.0%		+202 bp
EBITDA margin	7.2%	11.5%		+435 bp	8.2%	11.2%		+292 bp
EBIT margin	2.5%	7.5%		+492 bp	3.6%	7.1%		+350 bp
Net profit margin after MI	0.9%	5.9%		+505 bp	2.0%	5.5%		+344 bp

### Food segment profitability in 1-9 2018:

- **Normalized gross profit** → higher HRK 71m as a consequence of higher sales revenues and favorable sales structure,
- **Normalized EBIT** → higher HRK 88m, as a result of increase in sales of profitable categories, absence of share option expenses (amounted to HRK 10m in 1-9 2017) and lower selling and distribution cost resulting from i) changed business model in the MENA markets, ii) terminated business activities in the market of Tanzania, iii) lower depreciation and amortisation and iv) lower provisions for trade receivables,
- **Normalized net profit after MI** → higher HRK 85m due to, apart from aforementioned, lower interest expense and positive FX effects on borrowings, compensating for higher tax expenses.

One-off impacts in HRK <sub>m</sub>	1-9 2017	1-9 2018
Severance payments	(24)	(3)
Other expenses/(revenues) above EBIT	(1)	12
ESOP financial expenses	(2)	(2)
Deferred tax (assets)/liabilities	-	4

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process.

# Pharma profitability positively impacted by favourable sales structure

Pharmaceuticals segment (in HRK <sub>m</sub> )	REPORTED				NORMALIZED <sup>1</sup>			
	1-9 2017	1-9 2018	Δ	%	1-9 2017	1-9 2018	Δ	%
Sales revenue	611	639	28	4.7%	611	639	28	4.7%
Gross profit	304	316	12	4.0%	319	316	(3)	(0.9%)
EBITDA	84	99	14	16.9%	102	99	(3)	(3.3%)
EBIT	50	57	6	12.9%	71	57	(15)	(20.4%)
Net profit after MI	33	41	8	24.6%	55	42	(13)	(23.6%)
Gross margin	49.8%	49.5%		-29 bp	52.3%	49.5%		-278 bp
EBITDA margin	13.8%	15.4%		+161 bp	16.7%	15.4%		-128 bp
EBIT margin	8.3%	8.9%		+65 bp	11.7%	8.9%		-280 bp
Net profit margin after MI	5.5%	6.5%		+104 bp	9.0%	6.6%		-242 bp

## Pharmaceuticals segment profitability in 1-9 2018:

- **Normalized gross profit** → lower HRK 3m, but without a portion of new factory costs higher 4.2% due to higher sales revenues and positive impact of the sales structure itself,
- **Normalized EBIT** → lower HRK 15m, but higher HRK 2m without a portion of new factory costs. In addition to the aforementioned effects, an additional impact came from, among other, higher marketing expenses,
- **Normalized net profit after MI** → lower HRK 13m, but higher HRK 3m without a portion of new factory costs. An additional positive effect came from lower finance costs and lower minority interests, which compensated for higher tax expense.

One-off impacts in HRK <sub>m</sub>	1-9 2017	1-9 2018
New pharmaceuticals factory expenses +D&A	(15)	-
Severance payments	(6)	-
ESOP financial expenses	(0)	(0)

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process.

# Record high operating results fuelled by growth from Food segment

Podravka Group (in HRK <sub>m</sub> )	REPORTED				NORMALIZED <sup>1</sup>			
	1-9 2017	1-9 2018	Δ	%	1-9 2017	1-9 2018	Δ	%
Sales revenue	2,983	3,078	95	3.2%	2,983	3,078	95	3.2%
Gross profit	1,062	1,144	82	7.8%	1,077	1,144	67	6.3%
EBITDA	254	379	125	49.1%	297	371	73	24.7%
EBIT	110	239	128	116.0%	157	230	73	46.7%
Net profit after MI	54	186	132	243.8%	103	175	72	70.3%
Gross margin	35.6%	37.2%		+158 bp	36.1%	37.2%		+107 bp
EBITDA margin	8.5%	12.3%		+380 bp	10.0%	12.0%		+208 bp
EBIT margin	3.7%	7.8%		+405 bp	5.3%	7.5%		+222 bp
Net profit margin after MI	1.8%	6.0%		+423 bp	3.5%	5.7%		+225 bp

## Group profitability in 1-9 2018:

- **Normalized gross profit** → higher 6.3% (+7.8% without a portion of new factory costs) due to higher sales revenues and positive impact of sales structure itself,
- **Normalized EBIT** → higher HRK 73m (HRK +90m without a portion of new factory costs) as a consequence of i) the absence of share option expense, ii) lower selling and distribution cost and iii) higher marketing expenses,
- **Normalized net profit after MI** → higher HRK 72m (HRK +89m without a portion of new factory costs) as a result of, apart from aforementioned, lower finance cost and lower minority interest, which compensated for higher tax expense.

## One-off impacts in HRK<sub>m</sub>

	1-9 2017	1-9 2018
Severance payments	(30)	(3)
New pharmaceuticals factory expenses + D&A	(15)	-
Other expenses/(revenues) above EBIT	(1)	12
ESOP financial expenses	(3)	(2)
Deferred tax (assets)/liabilities	-	4

<sup>1</sup>Normalized for one-off impacts, normalization of results doesn't include potential tax impacts that would arise from the normalization process.


## Lower operating expenses as % of sales revenues

Operating expenses 18 vs. 17 % change	REPORTED	NORMALIZED <sup>1</sup>
Cost of goods sold (COGS)	0.7%	1.4%
General and administrative expenses (G&A)	(18.7%)	(8.6%)
Sales and distribution costs (S&D)	(1.1%)	(1.5%)
Marketing expenses (MEX)	7.8%	7.8%
Other expenses / revenues, net	(213.2%)	(54.8%)
<b>Total</b>	<b>(1.2%)</b>	<b>0.8%</b>

### Key highlights of normalized operating expenses in 1-9 2018:

- Cost of goods sold (COGS):**
  - Higher 1.4%, while without a portion of new factory cost in both periods, it would be 0.6% higher,
- General and administrative expenses (G&A):**
  - Lower 8.6% primarily as a result of lower staff costs and lower expenses of taxes and contributions not related to results,
- Sales and distribution expenses (S&D):**
  - Lower 1.5% due to: i) lower selling costs as a result of the changed business model in the MENA markets and terminated business activities in the market of Tanzania, ii) lower amortisation costs as a result of HRK 3.3m of distribution rights amortisation costs in 1-9 2017 that are not present in 1-9 2018,
- Marketing expenses (MEX):**
  - Growth of 7.8% mainly as a result of higher marketing activities in both business segments,
- Other expenses / revenues, net:**
  - In 1-9 2018, other income and expenses amounted to HRK +5m, while in the comparative period they amounted to HRK -4m. This line item includes foreign exchange differences from trade receivables and trade payables that amounted to HRK -13m in 1-9 2018, while in the comparative period they amounted to HRK -11m.

### Normalized expenses as % of sales revenues




<sup>1</sup>Normalized for one-off impacts.

## Further improvement of debt indicators

<i>(in HRKm)<sup>1</sup></i>	2017	1-9 2018	% change
Net debt	909	869	(4.4%)
Interest expense	27	21	(23.8%)
Net debt / normalized EBITDA	2.1	1.7	(18.2%)
Normalized EBIT / interest expense	9.3	15.8	69.5%
Equity to total assets ratio	57.2%	62.5%	+522 bp


Currency structure of debt as at 30 September 2018



### Key highlights:

- Net debt decrease → result of the repayment of a part of borrowings,
- Lower interest expenses → repayment of a part of borrowings and better refinancing conditions,
- Net debt/normalized EBITDA drop due to higher normalized EBITDA and lower net debt,
- **Weighted average cost of debt:**
  - As at 30 September 2018 → 1.7%,
  - As at 31 December 2013 → 4.3%.

Net debt components in HRKm as at 30 September 2018




<sup>1</sup>All P&L figures are calculated on the trailing 12 months level, while BS figures are taken at the end of period.

# Lower level of net cash from operating activities reflects working capital movement in 1-9 2018

Working capital movement in BS	30 September 2018 / 30 September 2017		Impact
Inventories		6.0%	<ul style="list-style-type: none"> <li>Impacted mainly by higher inventories of raw materials and supplies in the Pharmaceuticals segment (in line with the planned production dynamics in 2018) and the increase in inventories of finished products in the new Belupo factory,</li> </ul>
Trade and other receivables		(9.6%)	<ul style="list-style-type: none"> <li>Result of significant impairments at the end of 2017 related to receivables from the Agrokor companies in the amount of HRK 44 million, and better collection of receivables in the Pharmaceuticals segment,</li> </ul>
Trade and other payables		(1.3%)	<ul style="list-style-type: none"> <li>Lower HRK 8.5m compared to 30 September 2017.</li> </ul>

(in HRKm)	1-9 2017	1-9 2018	Δ
Net cash from operating activities	193	147	(46)
Net cash from investing activities	(171)	(69)	102
Net cash from financing activities	(181)	(294)	(112)
<b>Net change of cash and cash equivalents</b>	<b>(159)</b>	<b>(216)</b>	<b>(57)</b>

- **CAPEX** in 2018 is expected to be at the level of HRK 150m, in 2019 at the level of HRK 200 - 250m, and in 2020 and 2022 at the level of approximately HRK 200m.



## Contact

---

Podravka d.d.

Ante Starčevića 32, 48 000 Koprivnica, Croatia

[www.podravka.hr](http://www.podravka.hr)

Investor relations

[ir@podravka.hr](mailto:ir@podravka.hr)

tel: +385 48 65 16 65



# Podravka Group

*Always with a heart!*

Belgrade Stock Exchange Investor Conference, Belgrade, 15<sup>th</sup> November 2018

